Castle Biosciences, Inc. (CSTL) — Financial statements
Income statement, balance sheet, and cash flow for Castle Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 344↑3.7% | 332↑51.1% | 220↑60.4% | 137↑45.7% | 94 | |
| Cost of Revenue | 71↑18.0% | 60↑33.8% | 45↑40.5% | 32↑102.3% | 16 | |
| Gross Profit | 273↑0.5% | 272↑55.5% | 175↑66.4% | 105↑34.2% | 78 | |
| Operating Expenses | ||||||
| R&D Expenses | 52↓0.4% | 52↓2.9% | 54↑19.4% | 45↑51.5% | 30 | |
| General & Administrative Expenses | 91↑19.1% | 77↑15.2% | 66↑17.9% | 56 | 0.00 | |
| Selling & Marketing Expenses | 138↑11.9% | 123↑8.6% | 114↑31.2% | 87 | 0.00 | |
| SG&A Expenses | 229↑14.6% | 200↑11.0% | 180↑26.0% | 143↑64.9% | 87 | |
| Other Expenses | 35↑213.7% | 11↑23.2% | 9↑189.9% | -10↓611.8% | 2 | |
| Operating Expenses | 316↑20.1% | 263↑8.4% | 243↑36.5% | 178↑50.3% | 118 | |
| Total Costs & Expenses | 387↑19.7% | 323↑12.4% | 288↑37.1% | 210↑56.4% | 134 | |
| Operating Results | ||||||
| Operating Income | -43↓593.8% | 9↑112.8% | -68↑6.7% | -73↓81.8% | -40 | |
| Depreciation & Amortization | 41↑154.9% | 16↑29.7% | 12↑16.9% | 11↑209.5% | 3 | |
| EBITDA | 11↓70.3% | 38↑184.7% | -45↑22.8% | -58↓59.4% | -37 | |
| EBIT | -29↓232.9% | 22↑138.6% | -57↑16.7% | -69↓72.2% | -40 | |
| Interest & Other Income | ||||||
| Net Interest Income | 12↓5.3% | 12↑16.3% | 11↑168.6% | 4↑5797.0% | 0.07 | |
| Interest Income | 12↓8.9% | 13↑21.6% | 11↑167.7% | 4↑5735.3% | 0.07 | |
| Interest Expense | 0.09↓85.1% | 0.58↑5145.5% | 0.01↓35.3% | 0.02↑1600.0% | 0.00 | |
| Non-Operating Income | -13↑0.7% | -13↓26.8% | -11↓167.7% | -4↓5735.3% | -0.07 | |
| Other Income / Expenses | 13↑3.1% | 13↑21.5% | 11↑168.6% | 4↑5797.0% | 0.07 | |
| Income Before Tax | -30↓236.9% | 22↑137.6% | -57↑16.7% | -69↓72.2% | -40 | |
| Income Tax Expense | -5↓261.4% | 3↑3186.1% | 0.10↑105.7% | -2↑79.7% | -9 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -24↓232.4% | 18↑131.7% | -57↑14.4% | -67↓114.6% | -31 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -24↓232.4% | 18↑131.7% | -57↑14.4% | -67↓114.6% | -31 | |
| Bottom-Line Net Income | -24↓232.4% | 18↑131.7% | -57↑14.4% | -67↓114.6% | -31 | |
| EPS (Basic) | -0.83↓225.8% | 0.66↑130.8% | -2.14↑17.1% | -2.58↓108.1% | -1.24 | |
| EPS (Diluted) | -0.83↓233.9% | 0.62↑129.0% | -2.14↑17.1% | -2.58↓108.1% | -1.24 | |
| Weighted Average Shares | 29↑4.4% | 28↑3.6% | 27↑2.9% | 26↑3.6% | 25 | |
| Weighted Average Diluted Shares | 29↓0.9% | 29↑9.2% | 27↑2.9% | 26↑3.6% | 25 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.